An observational, retrospective, single center study of outcomes of Covid-19 infection in patients with B and plasma cell malignancies during the third wave in Argentina
Latest Information Update: 09 Aug 2022
At a glance
- Drugs AZD 1222 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 09 Aug 2022 New trial record
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association.